CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index



4 January 2018

Are we using the most sensitive outcome measures in pro-cognitive drug trials for schizophrenia?

The outcome measure selected for a pro-cognitive drug trial in schizophrenia must be sensitive enough to detect potentially subtle changes in cognition.

4 January 2018

Are we using the most appropriate trial designs for testing pro-cognitive drugs in schizophrenia?

Discussing the methodological considerations, and suggesting recommendations, for successful pro-cognitive drugs trials in schizophrenia.

4 January 2018

Are we recruiting the right patients with schizophrenia into pro-cognitive drug trials?

The importance of recruiting patients for pro-cognitive drug trials in schizophrenia on the basis of cognitive dysfunction. 

4 January 2018

Improving clinical trials for pro-cognitive drugs in schizophrenia

Introducing a blog-post series to discuss key limitations, and potential improvements, for pro-cognitive drug trials in schizophrenia.

21 December 2017

Decision-making under risk: from drugs to dopamine

How can you tell if a decision was impulsive or risky? Using the Cambridge Gambling Task to unpick how different brain regions, different drugs and different dopamine levels impact on decision-making. 

28 November 2017

Social cognition: an important but overlooked aspect of cognitive function

Social cognitive deficits have traditionally been linked with autism spectrum conditions. However, a recent paper from Cambridge Cognition suggests that deficits in social cognition are exhibited across a range of neurological, psychiatric and developmental disorders.

24 November 2017

What are the best ways to assess older adults’ cognitive health?

Exciting new research shows not only that web-based cognitive assessments are suitable for older adults but, for many, computerised assessments are actually preferable to traditional pen-and-paper tasks. 

Share this
webinar, web-based testing, wearables, voice-based assessment, voice recognition, virtual research, virtual clinical trials, trial design, translational neuroscience, translational cognitive tests, test-retest, technology, takeda, systematic review, social cognition, screening, scientific research, schizophrenia research, schizophrenia, risk-taking, research funding, remote testing, reliability, recruitment, prodromal, pro-cognitive, pre-screening, phase 3, pen-and-paper, patient-centric, patient screening, patient reported outcomes, patient recruitment, parkinson's disease, pal, paired associates learning, outcome measures, online, novel, neurotech, neuroscience, near-patient testing, mri and cognitive research, mood, modafinil, methodology, major depression, machine learning, lesion, innovation, innovate uk, icosr, high frequency, healthcare, gambling, ert, episodic memory, ebbinghaus, drug development, dopamine, digital tools, digital health, depression, dementias platform uk, dementia, deep and frequent phenotyping, decision-making, computerised testing, cognitive wellbeing, cognitive testing, cognitive science, cognitive safety, cognitive impairment, cognitive function, cognitive deficits, cognitive biomarkers, cognition kit, cns summit, cloud technology, clinical trials, clinical trial, cias, chronic pain, cgt, cardiovascular disease, cardiology, cantab research grant, cantab for clinical trials, cantab, cambridge gambling task, brain health, brain donor program, biomarkers, awards, automatic speech recognition, at-home testing, apple watch, amgen, alzheimer's disease, aaic,